<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="21741">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01960712</url>
  </required_header>
  <id_info>
    <org_study_id>2006/1142-31/3</org_study_id>
    <secondary_id>2006/1142-31/3</secondary_id>
    <nct_id>NCT01960712</nct_id>
  </id_info>
  <brief_title>The Role of Transpapillary Stenting in the Treatment of Bile Leakage After Liver Transection.</brief_title>
  <official_title>The Role of Transpapillary Stenting in the Treatment of Bile Leakage After Liver Transection.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Anders Jansson</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <authority>Sweden: Regional Ethical Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bile leakage after liver transection is treated by external drainage. The question addressed
      is whether downstream control by transpapillary stent insertion into distal bile duct can
      enhance healing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients who present with clinically significant bile leakage after liver resection at
      postoperative day two or longer are offered the opportunity to become randomized to either
      continuous external drainage or the addition of transpapillary stent.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of days of bile leakage from the abdominal cavity</measure>
    <time_frame>From intervention until day discharge from hospital</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>General complications rates. Postoperative hospital stay</measure>
    <time_frame>From intervention until day of discharge from hospital</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Bile Leakage</condition>
  <arm_group>
    <arm_group_label>Continued external drainage</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Continued external drainage alone.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continued external drainage + transpapillary stent</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>External drainage + transpapillary plastic stent (7-10 Fr).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transpapillary  plastic stent (7-10 Fr)</intervention_name>
    <description>Duodenoscopy plus transpapillary bile cannulation plus stent insertion.</description>
    <arm_group_label>Continued external drainage + transpapillary stent</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Liver resection including at least two liver segments.

        Exclusion Criteria:

          -  Hepatobiliary digestive anastomosis.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lars Lundell, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>14186</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 9, 2013</lastchanged_date>
  <firstreceived_date>September 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Lars Lundell</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
